Results 21 to 30 of about 8,244 (227)

Clinical and economic studies of eptifibatide in coronary stenting

Therapeutics and Clinical Risk Management, 2014
Tilak Pasala, Prasongchai Sattayaprasert, Pradeep K Bhat, Ganesh Athappan, Sanjay Gandhi The Heart and Vascular Center, Case Western Reserve University/MetroHealth, Cleveland, OH, USA Abstract: Platelet adhesion and aggregation at the site of coronary ...
Pasala T, Sattayaprasert P, Bhat PK, Athappan G, Gandhi S   +4 more
doaj   +1 more source

Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke. [PDF]

N Engl J Med
BACKGROUND Intravenous thrombolysis is a standard treatment of acute ischemic stroke. The efficacy and safety of combining intravenous thrombolysis with argatroban (an anticoagulant agent) or eptifibatide (an antiplatelet agent) are unclear. METHODS We
Adeoye O, Broderick J, Derdeyn CP, Grotta JC, Barsan W, Bentho O, Berry S, Concha M, Davis I, Demel S, Elm J, Gentile N, Graves T, Hoffman M, Huang J, Ingles J, Janis S, Jasne AS, Khatri P, Levine SR, Majjhoo A, Panagos P, Pancioli A, Pizzella S, Ranasinghe T, Sabagha N, Sivakumar S, Streib C, Vagal A, Wilson A, Wintermark M, Yoo AJ, Barreto AD.   +32 more
europepmc   +2 more sources

Eptifibatide, an Older Therapeutic Peptide with New Indications: From Clinical Pharmacology to Everyday Clinical Practice

International Journal of Molecular Sciences, 2023
Therapeutic peptides are oligomers or short polymers of amino acids used for various medical purposes. Peptide-based treatments have evolved considerably due to new technologies, stimulating new research interests.
Gašper Tonin, Jasna Klen
semanticscholar   +1 more source

A Heterozygous Variant in <i>HABP2</i> Causing Increased Risk of Arterial and Venous Thrombosis in a Young Male: Diagnostic and Therapeutic Challenges. [PDF]

Case Rep Med
Thrombosis is a major clinical issue, affecting venous and arterial circulation, increasing morbidity and mortality. While thrombophilia syndromes are established, new genetic polymorphisms in the hyaluronan binding protein 2 (HABP2) gene are not well understood.
Al-Busaidi S, Al-Maqrashi N, Al-Thihli K, Al Rawahi B, Al Farhan H, Al Alawi AM.   +5 more
europepmc   +2 more sources

Application of eptifibatide injection in acute ischemic cerebrovascular disease [PDF]

Xin yixue, 2022
Objective To evaluate the treatment effectiveness and safety of eptifibatide injection in the treatment of acute ischemic cerebrovascular disease （ICVD）.
Mei Ni, Tian Liang
doaj   +1 more source

Combined Approach to Eptifibatide and Thrombectomy in Acute Ischemic Stroke Because of Large Vessel Occlusion: A Matched-Control Analysis

Stroke, 2022
Background: In patients undergoing mechanical thrombectomy (MT), adjunctive antithrombotic might improve angiographic reperfusion, reduce the risk of distal emboli and reocclusion but possibly expose patients to a higher intracranial hemorrhage risk ...
G. Ma, Xuan Sun, Huiran Cheng, W. Burgin, W. Luo, W. Jia, Yajie Liu, Wenlong He, Xiaokun Geng, Liangfu Zhu, Xingyu Chen, Huaizhang Shi, Haowen Xu, Litong Zhang, Anxin Wang, D. Mo, N. Ma, F. Gao, Ligang Song, X. Huo, Yiming Deng, Lian Liu, G. Luo, Baixue Jia, X. Tong, Liping Liu, Zeguang Ren, Z. Miao   +27 more
semanticscholar   +1 more source

Eptifibatide use in ischemic stroke patients undergoing endovascular thrombectomy: A matched cohort analysis

Frontiers in Neurology, 2022
Introduction Small studies have suggested that eptifibatide (EPT) may be safe in acute ischemic stroke (AIS) following intravenous thrombolysis or during endovascular therapy (EVT) for large vessel occlusion (LVO).
Ameena Rana, Siyuan Yu, Savina Reid-Herrera, Scott Kamen, K. Hunter, H. Shaikh, T. Jovin, Olga R Thon, Parth Patel, J. Siegler, Jesse M. Thon   +10 more
semanticscholar   +1 more source

Results of a pilot clinical trial of the safety and efficacy of an original glycoprotein IIb/IIIa receptor inhibitor in acute coronary syndrome

Кардиоваскулярная терапия и профилактика, 2023
Aim. To study the safety and efficacy of Angipure in acute ST-segment elevation coronary syndrome (STE-ACS) and high-risk percutaneous transluminal coronary angioplasty (PTCA) compared with eptifibatide.Material and methods.
S. V. Lukyanov, Yu. F. Glukhov, E. V. T., B. M. Tankhilevich, D. A. Zateyshchikov, T. V. Khlevchuk, I. B. Bondareva   +6 more
doaj   +1 more source

In vitro and patient studies with platelets to explore off-target cardiovascular effects of integrase inhibitors. [PDF]

HIV Med
Abstract Introduction People with HIV currently face a tenfold higher risk of developing cardiovascular disease (CVD) than those without HIV. Studies have shown various off‐target effects of antiretroviral treatment (ART) on the cardiovascular system, but little is known about the effects of currently used integrase strand transfer inhibitors (INSTIs ...
Keniyopoullos R, Khawaja AA, Boffito M, Emerson M.   +3 more
europepmc   +2 more sources

Effects of two different glycoprotein platelet IIb/IIIa inhibitors and the clinical endpoints in patients with intracranial Pipeline flow diverter implant

Journal of Interventional Medicine, 2020
Objective: To compare the antiplatelet effect and major adverse cerebrovascular events of Pipeline for intracranial aneurysms using glycoprotein IIb/IIIa antagonists (GPI) eptifibatide and tirofiban.
Qiao Deng, Shichao Zhang, Mingzhou Li, Guozhong Zhang, Wenfeng Feng   +4 more
doaj   +1 more source